Effects of Glutamate and Aspartate on Ataxic Gait Induced by 3-Acetyl Pyridine in Rats

G. DE MICHELE, F.B. JOLICOEUR, D.B. RONDEAU, R.F. BUTTERWORTH and A. BARBEAU

INTRODUCTION

Administration of 3-acetyl pyridine (3-AP), a nicotinamide antagonist (Hicks, 1955), produces within 24 hrs, a destruction of the inferior olivary nucleus (Desclin, 1974) with a consequential loss of climbing fibers to the cerebellum (Desclin and Escubi, 1974). These histological changes resemble those observed in olivo-cerebellar atrophy (Holmes, 1907).

The two acidic amino acids, aspartate and glutamate, have been considered as possible candidates for a neurotransmitter role in the climbing fibers (Guidotti et al., 1975; Nadi et al., 1977). Levels of glutamate and aspartate in brains of 3-AP treated animals have been examined in several studies and decreased cerebellar concentrations of both amino acids have been reported (Butterworth et al., 1978; McBride et al., 1978; Rea et al., 1980). Similar decreases in aspartate and glutamate have been found in cerebellum, brain, and spinal cord of Friedreich’s ataxia patients (Robinson, 1968; Huxtable et al., 1979).

The administration of 3-AP to animals produces a marked ataxic gait and other neurological signs which have been quantified and described in detail recently (Jolicoeur et al., 1979). The ataxic syndrome may be a consequence of decreased concentrations of glutamate and of aspartate in the cerebellum of 3-AP treated rats. The main purpose of this study was to examine the effects of intraventricular injections of aspartate and glutamate on ataxia induced by 3-AP.

EXPERIMENT I

In this experiment, we examined the effects of 1.62 μm of aspartate and of glutamate on both relatively mild and severe ataxic gaits which were induced by 32.5 and 65 mg/kg 3-AP respectively. The dose of aspartate and glutamate was selected on the basis of preliminary experiments which indicated that neither amino acid, given in this amount, produced any sign of toxicity in animals.

Methods

One hundred and eight male albino rats, 275-300 g. in weight, were used. They were implanted under pentobarbital anesthesia with an indwelling cannula (26 gauge) into the left brain ventricle. A recovery period of at least 36 hrs was given before treatments were initiated.

On Treatment Day, animals were injected intraperitoneally with either .9% NaCl, 32.5 mg/kg 3-AP or 65 mg/kg 3-AP. Three groups of 12 animals were assigned to each treatment. Liquid 3-AP (Sigma chemicals) was mixed with .9% NaCl to obtain an injection volume of 1 ml/kg.

Twenty four hours later, on Test Day, the animal’s walking gaits were measured. For that purpose, animals with their hindfeet stained with ink, were walked through an enclosed 90 cm long corridor with a paper covered floor. The angle between consecutive and contralateral ink marks, representing the animal’s steps, was then calculated. A detailed description of this procedure has been published (Jolicoeur et al., 1979). After a first recording of walking patterns, animals were injected intraventricularly with either .9% saline, 1.32 μm glutamate, or 1.32 μm aspartate. Three groups of animals, each having received a particular treatment on Treatment Day, were assigned to the various injections. Animal’s gaits were measured immediately following injections as well as 1 hr after. Glutamate and...
aspartate were dissolved in .9% NaCl and pH of solutions was adjusted with sodium hydroxide. Intraventricular injections were performed by means of 50 µl Hamilton syringe, linked to the animal's cannulas with PE-20 polyethylene tubing. Volumes of injections were 10 µl, given over a 30 sec. period.

Results

Data obtained with each set of three groups given a particular treatment on Treatment Day, were analysed by individual two way ANOVA's for repeated measures (Winer, 1971). Factors included in each analysis were injections and test period. Each of the three injections given on the Test Day, injections and test period. Each of the gait measurements, constituted one level of the injection factor. Each of the gait measurements, performed before, immediately following injections, and 1 hr after injections, contributed to one level of the test period factor. For the groups administered .9% NaCl, the critical injection by test period interaction was significant (P<0.05). This interaction was examined by performing simple main effect analyses at each level of both factors and by comparing individual groups by means of Dunnett tests. These tests revealed that for the two groups injected with glutamate and aspartate, angles of gait immediately following injections were significantly larger than those measured prior to injection (P<0.01). No other significant differences were found.

For the groups treated with 32.5 mg/kg 3-AP, the injection by test period interaction was also significant (P<0.01). Follow up analyses indicated that immediately following injections, the angles of the groups injected with aspartate and glutamate were significantly increased in comparison to the group injected with .9% NaCl (P<0.01). Also, for both glutamate and aspartate groups, the angles following injection were significantly larger than those measured prior to injections (P<0.05). At the 1 hr post injection test period, the animals injected with aspartate still displayed a significantly enlarged gait angle (P<0.01).

A significant injection by test period interaction was also found for the groups treated with 65 mg/kg 3-AP (P<0.01). Subsequent analyses revealed that in comparison to the group given .9% NaCl, the gait angles of both glutamate and aspartate groups were significantly increased immediately following as well as 1 hr after injections (P<0.05).

In summary, the preceding statistical analyses indicate that both aspartate and glutamate can significantly improve the walking gait of 3-AP treated animals.

EXPERIMENT 2

The results of the preceding experiment indicate that both glutamate and aspartate can significantly improve the walking gait of 3-AP treated animals. In the course of the experiment, it was observed that the administration of both amino acids induced a strong forward locomotion in the animals. This effect was of short duration but was present at the time the animals' gaits were recorded. It is possible that the amelioration of walking gaits was secondary to the sudden increase in locomotor activity induced by glutamate and aspartate. Therefore, it seemed warranted to examine the effects of other substances known to increase locomotor activity in rats. In the second experiment, the effects of Substance P (SP), thyrotropin releasing hormone (TRH), apomorphine and amphetamine on the walking gaits of animals treated with 32.5 mg/kg 3-AP were examined.

Methods

Methods and procedures were similar to those employed in the first experiment. Twelve cannulated rats were injected with 32.5 mg/kg 3-AP.

**Figure 1** — Mean gait angles (in degrees) presented as a function of various treatments of experiment 1. Angles were measured immediately before (PRE) and after (INJ) injections, as well as 1 hr after (POST).

**Figure 2** — Schematic representations of walking gait of experimental and control animals of Experiment 1 and 2. Experimental animals were injected acutely with 32.5 mg/kg of 3-acetyl pyridine on Treatment Day and were administered either .9% NaCl, Glutamate (1.32 µM), Aspartate (1.32 µM) or Substance P (0.6 µg) on Test Day.
Twenty four hours later, animals received each of the following treatments in a counterbalanced order: SP (0.6 μg); TRH (10 μg); amphetamine (1 mg/kg) and apomorphine (0.5 mg/kg). A period of two hours was interspersed between each injection. SP and TRH were injected intraventricularly in a volume of 10 μl. Apomorphine and amphetamine were administered subcutaneously and intraperitoneally, respectively, in volumes of 1 ml/kg. All substances were dissolved in 0.9 percent NaCl. Prior to each injection, locomotor activity was first measured for 2 min in a photocell apparatus, and walking gaits were recorded. Activity and gaits were then measured within 20 min following each injection.

Results

A preliminary variance analysis indicated that the animals’ activity scores and walking gaits did not differ significantly in the test periods preceding each of the four injections. Because of this, data of all four pre-injection test period were combined for each animal.

For both activity and gait, results were analyzed by means of individual ANOVA’s for repeated measures (Winer, 1971). Five levels of the factor were included in each analysis: combined pre-injection data and results obtained following each of the four injection treatments. A significant main effect for activity scores was found (P<0.01). Post hoc tests indicated that the gait angles following SP administration were significantly larger than those of the pre-injection test period. The other injection treatments did not significantly affect the ataxic gait of 3-AP animals.

Results for both activity and gait, obtained in each experimental condition, are presented in Table 1. In summary, the results of this experiment indicate that, although all four injection treatments significantly increased locomotor activity of 3-AP treated rats, only SP was able to ameliorate significantly the ataxic gait of these animals.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Activity</th>
<th>Pre-injection</th>
<th>Injection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Substance P</td>
<td>13.2 ± 3.2</td>
<td>45.0 ± 8.2**</td>
<td>86.9 ± 4.6</td>
</tr>
<tr>
<td>TRH</td>
<td>11.0 ± 2.7</td>
<td>91.6 ± 9.3**</td>
<td>85.1 ± 5.7</td>
</tr>
<tr>
<td>Apomorphine</td>
<td>14.5 ± 3.8</td>
<td>39.0 ± 5.6*</td>
<td>92.1 ± 3.9</td>
</tr>
<tr>
<td>Amphetamine</td>
<td>10.0 ± 3.3</td>
<td>34.5 ± 6.0*</td>
<td>89.6 ± 4.3</td>
</tr>
</tbody>
</table>

* P < 0.05
** P < 0.01

Post hoc tests indicated that the gait angles following SP administration were significantly larger than those of the pre-injection test period. The other injection treatments did not significantly affect the ataxic gait of 3-AP animals.

Discussion

Results of the first experiment demonstrated that glutamate and aspartate can significantly improve the walking gait of animals rendered ataxic by 3-AP. The improvement in gait was due to an enlargement of the reduced gait angle of 3-AP treated animals (Fig. 1). The enhancing effects of glutamate and aspartate on gait angles was not specific to animals administered 3-AP, since it was also seen following administration of SP. However the effects of this peptide were not as pronounced as those of glutamate and aspartate. As can be seen in Fig. 2, the ataxic gait pattern of 3-AP treated animals was not reversed as completely by SP as it was with glutamate and aspartate.

In summary, the ataxic walking gait of animals treated with 3-AP was improved markedly by glutamate, aspartate and, to a lesser extent, SP. The mechanism by which these substances exerted this effect is unknown at the present time. Whether or not the observed effects reflect a direct pharmacological action on the mechanisms underlying 3-AP induced ataxia, remains to be determined. Further studies using different animal models of ataxia and other pharmacological tools should help to delineate the specificity and the nature of the effects observed in this study.

Acknowledgements

Supported by l’Association Canadienne de l’Ataxie de Friedreich. G.D.M. is a scholar of Ministry of Health, Italy. F.B.J, is a Fellow of the Huntington Society of Canada.

References


